Exabis Library
Welcome to the e-CCO Library!
P598: The utility of the “Low Anterior Resection Syndrome SCORE” in assessing the postoperative outcomes of patients undergoing restorative proctocolectomy with ileal pouch anal-anastomosis for Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P599 Trimester exposure and pregnancy outcomes in women exposed to golimumab: Results from the company pharmacovigilance database
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P599: Azathioprine in the prevention of anti-infliximab antibody formation: A pilot dose-finding study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P599: Development of an inflammatory bowel disease-specific nutrition screening tool (IBD-NST)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P599: Home testing for faecal calprotectin: follow-up results from the first UK trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P599: Perspectives on disease- and treatment-related issues encountered by patients with Inflammatory Bowel Disease: a qualitative concept mapping study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P599: Short- and long-term outcome of minimally invasive approach for Crohn’s disease: Comparison between single incision, robotic-assisted and conventional laparoscopy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P599: Similar efficacy of mesalazine in adult and elderly patients: post-hoc analysis of randomised non-inferiority trial of 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P600 Vedolizumab dose optimisation: Findings from a Belgian registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P600: Clinical utility of anti-IFI16 seroreactivity in the response to anti-TNF therapy in IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P600: Democratic deliberation to assess Veteran preferences for biosimilar medication switching for the treatment of Inflammatory Bowel Disease in a resource-conscious setting.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P600: Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P600: Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P600: Serologic response to COVID-19 vaccines in IBD patients: a prospective study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P600: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study from Finland
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P601: Are Inflammatory Bowel Disease patients’ expectations met by dietetic services?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P601: Can Amitriptylin improve the quality of life in patients with Crohn's disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P601: Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P601: Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM